effect of celery seed on obesity and fatty liver

Survey the Effect of celery seed on serum levels of hepatic enzymes, lipid profile, glycemic parameters and hepatic steatosis degree in nonalcoholic fatty liver disease patients, with overweight and obesity

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20191124045488N1

Enrollment

Registered

2019-11-29

Start date

2019-12-07

Completion date

Unknown

Last updated

2019-12-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-alcoholic fatty liver disease. Fatty (change of) liver, not elsewhere classified

Interventions

Intervention 1: Intervention group: getting 4 capsule of celery seed (500mg) per day fo 6 weeks. Intervention 2: Control group: getting 4 capsules of plasebo for 6 weeks.

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Overweight and obese patients (with BMI> 25) With nonalcoholic fatty liver (grade 1, 2) having ultrasound sheet with diagnosis of nonalcoholic fatty liver with radiologist and gastroenterologist approval

Exclusion criteria

Exclusion criteria: Pregnancy and lactation liver transplantation cigarette smoking, alcohol and drugs use medications such as corticosteroids, amiodarone, tamoxifen, pracacillin, methotrexate complete intravenous nutrition heart failure, kidney disease, thyroid failure Hemochromatosis and Wilson disease Having positive test for hepatitis C, B and autoimmune hepatitis alpha-antitrypsin deficiency

Design outcomes

Primary

Measure	Time frame
Hepatic enzymes (AST, ALT). Timepoint: Before and after intervention. Method of measurement: Use of enzymatic kits.;Lipid profile (Triglyceride, total cholesterole, LDL, VLDL, HDL). Timepoint: Before and after intervention. Method of measurement: Use of enzymatic kits.;Insulin levels. Timepoint: Before and after intervention. Method of measurement: Use of enzymatic kits.;Liver Echogenicity. Timepoint: Before and after intervention. Method of measurement: Using an ultrasound machine by a radiologist.;The total amount of calorie received. Timepoint: Before and after intervention. Method of measurement: Using a 24-hour food recording questionnaire.;Hs-CRP. Timepoint: Before and after intervention. Method of measurement: Use of enzymatic kits.;Body fat percentage. Timepoint: Before and after intervention. Method of measurement: Using body composition measuring device.;Weight. Timepoint: Before and after intervention. Method of measurement: Using digital scales.;Waist and hip circumference. Timepoint: Before and after intervention. Method of measurement: Use non-elastic tape meters.;Fasting Blood sugar. Timepoint: Before and after intervention. Method of measurement: Use of enzymatic kits.;HOMA-IR. Timepoint: Before and after intervention. Method of measurement: HOMA-IR=BS(mmol/lit)×insulin(microunit/lit)/22.5.	—

Measure

Time frame

Hepatic enzymes (AST, ALT). Timepoint: Before and after intervention. Method of measurement: Use of enzymatic kits.;Lipid profile (Triglyceride, total cholesterole, LDL, VLDL, HDL). Timepoint: Before and after intervention. Method of measurement: Use of enzymatic kits.;Insulin levels. Timepoint: Before and after intervention. Method of measurement: Use of enzymatic kits.;Liver Echogenicity. Timepoint: Before and after intervention. Method of measurement: Using an ultrasound machine by a radiologist.;The total amount of calorie received. Timepoint: Before and after intervention. Method of measurement: Using a 24-hour food recording questionnaire.;Hs-CRP. Timepoint: Before and after intervention. Method of measurement: Use of enzymatic kits.;Body fat percentage. Timepoint: Before and after intervention. Method of measurement: Using body composition measuring device.;Weight. Timepoint: Before and after intervention. Method of measurement: Using digital scales.;Waist and hip circumference. Timepoint: Before and after intervention. Method of measurement: Use non-elastic tape meters.;Fasting Blood sugar. Timepoint: Before and after intervention. Method of measurement: Use of enzymatic kits.;HOMA-IR. Timepoint: Before and after intervention. Method of measurement: HOMA-IR=BS(mmol/lit)×insulin(microunit/lit)/22.5.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMahsa Samadani

Ahvaz University of Medical Sciences

samadani.m@ajums.ac.ir+98 71 3648 0181

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026